Archive | May, 2017

A Winning Formula for Raising Capital

11 May

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

As LSN heads into its fifth year, we have seen what works and what doesn’t in the fundraising process. LSN has developed a fundraising platform consisting of an early stage life science investor database (the LSN Investor Platform), and the RESI conference series, which takes place every two and a half months at venues through out North America. These two vehicles allow fundraising executives the ability to be very efficient in finding investors and partners that are a fit for their stage of development and their product offering.

Providing an efficient vehicle for identifying and understanding global investors that are a fit for your company is very helpful, but quite frankly is just the ante into the game. The devil is in the details and this is where we see many scientist entrepreneurs fall short on their capital raising efforts. I have proclaimed time and time again that raising money is a numbers game, and that theme is ever present in the basic process of getting in front of investors. Not surprisingly, it’s all about the frontend, making that introductory calls and the backend, doing the all-important follow-up calls. These two pieces of the process always prove to be the most daunting because of the tedious and repetitive nature of this simple activity.

I have advised many of my fundraising clients that it is essential to find someone in their organization who enjoys scheduling meetings and following up regarding meetings. It sounds easy but is far from it. Everybody is busy and everybody is trying to prioritize their schedule around their to-do lists of important tasks. Therefore it takes someone who is genetically coded to handle the setting up and follow up, someone who doesn’t interpret a “no” just because they haven’t received an answer back. Someone who has a “can do” attitude of going after a meeting until they get it booked or get an emphatic, no thanks, and it’s off the table. It can take 3, 5, 10, or 20 attempts to book or follow up on a meeting so having the right personality for this mission is critical. I routinely suggest if no one in-house is available or capable of performing these tasks then hire an intern or recent college grad who is looking to get some exposure and training on the business side of the house. Having a CEO or a business development executive trying to arrange meetings is too time intensive and doesn’t work (there I said it).

In summary, if you have a current accurate database of global investors and an ongoing conference series to attend, the crucial next step is doing the hard work to get you and your story in front of the right investors. Don’t underestimate the tenacity needed to participate in the numbers game called fundraising.

Pitchbook vs. LSN Investor Platform

11 May

By Cole Bunn, Senior Research Analyst, LSN

cole-wpLife Science Nation’s investor platform and Pitchbook both offer various data on early-stage investors which get used by a variety of different stakeholders in the industry. Although there is some overlap in the data tracked by these platforms, there lies stark differences in how the data is sourced, updated, and the industry specific nature of the data. These core differences result in two different types of platforms that serve different purposes. Pitchbook’s utility lies mostly in providing a high-level overview of different markets/sectors whereas the value in the LSN platform is providing actionable, industry-specific data.

The LSN investor platform is focused solely on the early-stage life science space

While Pitchbook and other data providers focus on the overall private market’s landscape, LSN investor platform is specifically focused on seed and venture-stage (series A, B) companies in the life science space which we define as therapeutics, medical devices, diagnostics, research tools and healthcare IT. LSN’s highly-specific focus has allowed for the development of a platform that captures the most critical data points for entrepreneurs seeking compatible investors. In addition, LSN’s expertise has led to a highly efficient search ontology capable of searching the space on a more specific level. LSN’s investor profiles are tagged in terms of Sector, Subsector, Indication, Product Phase-of-Development, Geographical exposure, investment size and several other variables that are of importance to a fundraising entrepreneur.

LSN captures more than data

Pitchbook obtains their information through web-crawlers and surveys. These methods have two main problems 1) primarily historical data 2) no reliable method for keeping data up-to-date. While this does provide their database with a great volume of data, it falls behind LSN’s platform in terms of depth. The LSN platform achieves great depth by supplementing the publicly available information with interviews performed by a dedicated team of research analysts that identify new capital sources allocating to early-stage life science companies, to parse out investment preferences. In addition to the depth of data this allows LSN’s team to gather, maintaining a personal relationship through an ongoing dialogue and involvement in the RESI conference series provides a direct benefit to LSN’s fundraising clients. This personal connection between the LSN research team and an investment firm/group allows LSN to capture and utilize a unique flow of information and provides an unmatched tool for fundraising CEOs to understand the players in their space, their nuanced preferences/strategies and a way to begin a dialogue with them.

LSN team is a value add

Pitchbook data is a tool that provides its users a way to take the pulse of a certain industry. Along with a way for entrepreneurs to quickly survey the investment landscape and identify relevant groups, a subscription to the LSN investor platform grants licensees a comprehensive onboarding meeting with the LSN team that covers best practices for using the platform, light marketing/messaging consultation, as well as some assistance in finding a few highly-targeted leads. These meetings also inform the LSN research team of exactly what our clients are working on, allowing them to tailor their surveys to better understand the investors’ interest level in current clients. Finally, all investor accounts are tagged with both a date and the analyst responsible for the account. Any entrepreneurs with questions or concerns around the profile or firm are encouraged to contact the analyst on the profile.

LSN Platform + the RESI Conference

The biggest differentiator among the LSN investor platform, Pitchbook and other similar data providers, and the biggest value driver, is the intertwined relationship between the LSN and the RESI conference series. The RESI conference is an early-stage investment/partnering event that allows entrepreneurs to meet face-to-face with up to 16 relevant investors in one day, and is powered by the LSN investor platform and LSN’s relationships with these groups. All data on an investment firm’s preferences are used to populate the investor’s profile in the RESI partnering system, allowing for a more effective match-making process. Using the LSN platform and RESI conference in parallel allows fundraising CEOs to identify a variety of capital sources in their space, begin a dialogue with these groups and continue to strengthen these relationships through in-person meetings at RESI conferences.

Orphan Drug Investors Share Their Insights at RESI San Diego

11 May

By Lucy Parkinson, Director of Research, LSN

Orphan diseases present a unique opportunity for a biotech investor; faster development, market exclusivity and the possibility of delivering a cure to patients with no current treatment options. However, these small markets also present unique challenges in development and strategy.

At RESI San Diego, five experienced investors who specialize in rare disease opportunities will explain their strategies in the sector. These investors will explore how they identify potential in a rare disease therapeutic, and how they turn tiny markets into significant ROI.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital, panelists include:

Hot Investor Mandate 1: Global Venture Capital Firm Invests in Therapeutics, Devices and Healthcare IT

11 May

A global venture capital firm based in Menlo Park, California with additional offices worldwide has approximately $3.5 billion in total assets across 10 funds, and the most recent fund closed at over $600 million. The firm focuses on making equity investments into the life science and technology spaces from seed to late venture stage. The investment size is varied, and typically it ranges from $1 million to $20 million. The firm will invest in companies based in the US, India and Israel.

The firm is currently looking for new opportunities in the Biotech Therapeutics, Medical Devices and Healthcare IT sectors. The firm will also consider Diagnostics, but that will not be its focus. For Therapeutics and Medical Devices, the firm is extremely opportunistic in terms of subsectors and indications. The firm is interested in companies targeting orphan diseases. The firm is generally looking for companies in the clinical stage of development, but it also considers preclinical companies one or two years from clinics, as well as near companies near commercial stages dependent on the case.

The firm primarily invests in private companies, and considers pre-revenue companies. The firm doesn’t have specific requirements for company’s management team or revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Private Investors Back New Healthtech Opportunities in Latin America

11 May

A group of private investors dedicated to funding, mentoring, and building new HealthTech startups is based in Buenos Aires, Argentina with additional offices in the US and Europe. The firm makes equity investments from its pilot fund and provides mentorship, technical expertise, and business advisory for seed and early stage companies. The firm is currently seeking new opportunities throughout Latin America.

The firm focuses on companies at the intersection of healthcare and the computer/consumer electronic world. The firm works with concept and venture projects to prove technical and market feasibility, develop sound business models, attract permanent senior management, provide industry contacts, and bring in additional angel or venture capital financing. Current portfolio includes gaming software, wearable devices, and mobile applications. The firm would also consider medical devices that do not require regulatory approval and can get to market quickly. The firm typically avoids therapeutics. The firm’s current portfolio includes 3 companies, all of which involve apps or a device that is integrated with an app.

The firm is looking for top talents in healthcare and information technology with novel, disruptive ideas. The firm’s members are very involved with the investee company by acting as strategic advisors, board members, and board observers to prove technical and market feasibility, develop sound business models, attract permanent senior management, provide industry contacts, and bring in additional angel or venture capital financing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Pharma Firm Seeks New Drugs in Thrombosis, Pain, Opthalmology, Rare Diseases, And More

11 May

A global pharmaceutical company headquartered in Tokyo, Japan is currently looking for partnering and in-licensing opportunities across the globe.

The firm is currently looking for innovative therapeutics targeting the following priority areas: Thrombosis & Thrombolysis, Pain, Cardio-Renal, Ophthalmology and rare diseases. Other interest areas include metabolic diseases, oncology, organ fibrosis and NAFLD/NASH, neurology, immunology, and mitochondrial disease. The firm is open to biologics or molecular targets, with an increased interest in new platform technologies. The following areas are currently out of focus: hypertension, thrombosis, dyslipidemia, psychiatric diseases, and immunodeficiency.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Northeast Venture Firm Focuses on Software Enabled Devices

11 May

A Venture Capital firm based in Massachusetts manages a total of $70 million across 3 funds and is structured to make investments ranging from $500,000 to $1 million into companies raising rounds sizes in the $3-5 million range. The firm also has the ability to provide capital in follow on situations when appropriate through its own resources and its network of syndicates. The firm primarily invests in the Northeastern US although they have also invested in companies throughout the United States.

The firm focuses on healthcare IT, life science tools, medical devices and diagnostics companies. The firm is most actively interested in companies in the healthcare IT space and software enabled devices, and they look much more selectively at companies in the medical device and diagnostics spaces. The firm generally gets involved in the seed or series A round and is open to all indications.

The firm looks for privately held companies with experienced management teams. The firm looks to work side by side with entrepreneurs helping them form strategic relationships, recruit management talent, and assemble vital resources necessary for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com